The stock of Knight Therapeutics Inc (TSE:GUD) is a huge mover today! About 372,962 shares traded hands or 188.87% up from the average. Knight Therapeutics Inc (TSE:GUD) has risen 9.62% since March 31, 2016 and is uptrending. It has outperformed by 8.53% the S&P500.
The move comes after 5 months positive chart setup for the $1.20B company. It was reported on Nov, 4 by Barchart.com. We have $11.70 PT which if reached, will make TSE:GUD worth $348.00M more.
Knight Therapeutics Inc (TSE:GUD) Ratings Coverage
Out of 2 analysts covering Knight Therapeutics (TSE:GUD), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $10 is the highest target while $9.50 is the lowest. The $9.75 average target is 7.50% above today’s ($9.07) stock price. Knight Therapeutics has been the topic of 2 analyst reports since May 12, 2016 according to StockzIntelligence Inc.
More notable recent Knight Therapeutics Inc (TSE:GUD) news were published by: Reuters.com which released: “Exclusive: Endo considers sale of Paladin Labs to Knight Therapeutics – so…” on November 04, 2016, also Seekingalpha.com with their article: “How Many Times Can Knight Therapeutics Issue Equity?” published on September 22, 2016, Seekingalpha.com published: “Put Knight Therapeutics On Your Watchlist” on April 01, 2016. More interesting news about Knight Therapeutics Inc (TSE:GUD) were released by: Prnewswire.com and their article: “Braeburn Pharmaceuticals and Knight Therapeutics Announce Canadian Sublicense …” published on February 01, 2016 as well as Businesswire.com‘s news article titled: “Antibe Enters into a GUD Product Licensing Agreement with Knight Therapeutics” with publication date: November 16, 2015.
Knight Therapeutics Inc is a Canada pharmaceutical company. The company has a market cap of $1.20 billion. The Firm is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It has a 55.73 P/E ratio. It finances other life sciences companies in Canada and internationally.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.